pioglitazone has been researched along with Carcinoma, Transitional Cell in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, R | 1 |
| Metcalfe, MJ | 1 |
| Ferguson, JE | 1 |
| Mokkapati, S | 1 |
| Nogueras González, GM | 1 |
| Dinney, CP | 1 |
| Navai, N | 1 |
| McConkey, DJ | 1 |
| Sahai, SK | 1 |
| Kamat, AM | 1 |
1 other study available for pioglitazone and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Effects of thiazolidinedione in patients with active bladder cancer.
Topics: Aged; Carcinoma, Transitional Cell; Cystectomy; Diabetes Mellitus; Disease-Free Survival; Female; Hu | 2018 |